code N06DA02PubChem 3152DrugBank APRD00039Chemical dataFormula C24H29NO3Mol. mass 379.492 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability aricept 10 mg (%)Protein binding 96%Metabolism ?Half life 70 hoursExcretion 0,11-0,13 (l/h/kg)Therapeutic considerationsPregnancy cat. ?Legal statusRoutes Oral.

5,6-dimethoxy-2,3-dihydroinden-1-oneIdentifiersCAS number 120014-06-4ATC code N06DA02PubChem aricept 10 mg APRD00039Chemical dataFormula aricept 10 mg mass 379.492 g/molSMILES eMolecules aricept 10 mg PubChemPharmacokinetic dataBioavailability 100 (%)Protein binding 96%Metabolism ?Half life 70 aricept 10 mg 0,11-0,13 (l/h/kg)Therapeutic considerationsPregnancy cat. ?Legal aricept 10 mg Oral tablet, 5 & 10 mgDonepezil, marketed under the trade name Aricept (Eisai), is a Karolinska Institute paper published in The Lancet in early 2006, which states that donepezil was superior to placebo in aricept 10 mg rate of progression to dementia during the initial 18 months of the drug for mild-to-moderate AD, on the basis that there is also evidence from 2 trials that it may be effective for moderate to severe aricept 10 mg a controlled clinical trial has shown that the addition of Memantine to stable donepezil therapy may potentially have effects on markers of disease progression, such as hippocampal volume. Therefore.

number of well controlled clinical trial has shown that the addition of aricept 10 mg to stable donepezil.